Drug Profile
Orilotimod potassium
Alternative Names: Apo-805; Apo-805K1Latest Information Update: 09 Jun 2015
Price :
$50
*
At a glance
- Originator ApoPharma
- Class Antipsoriatics; Essential amino acids; Potassium compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 01 Oct 2013 ApoPharma completes a phase II trial in Plaque psoriasis in USA (NCT01483924)
- 30 Nov 2011 Phase-II clinical trials in Plaque psoriasis in USA (PO)